Strain-specific detection of Mycoplasma gallisepticum: A duplex qPCR assay for vaccine efficacy and infection surveillance Authors: Pengcheng Fan, Ziqing Liu, Yi Xu, Mengjiao Guo, Chengcheng Zhang, Zongyi Bo, Yantao Wu, Xiaorong Zhang Published: 2026 ABSTRACT AbstractMycoplasma gallisepticum (MG) is a major pathogen of poultry that causes substantial economic losses to the global poultry industry. Vaccination with live attenuated vaccines is currently a core strategy for controlling MG infection in chickens. In China, the officially approved MG vaccine strains for poultry use include F-36, TS-11, and 6/85. Following vaccination, effective methods are required to evaluate vaccine strain colonization and differentiate wild-type from vaccine strain infections. To address this unmet need, we developed a set of rapid, specific duplex quantitative PCR (qPCR) methods based on MGB probes. This method can discriminate between wild-type MG and all three currently used major vaccine strains, and users can select the corresponding specific duplex combination according to the vaccine strain adopted in field production. First, we compared whole-genome sequences of wild-type MG and vaccine strains, and successfully identified strain-specific polymorphic sites. Next, we designed and optimized specific primers and MGB probes targeting these polymorphic sites. Using the developed primer-probe sets, we established three independent duplex qPCR assays, each of which enables simultaneous detection of one specific vaccine strain and wild-type MG. Validation experiments confirmed that all three assays have high specificity, sensitivity, and reproducibility. When applied to DNA extracted from clinical chicken choanal cleft swab samples, this method successfully differentiated between wild-type MG infection and vaccine strain exposure. In conclusion, this novel assay provides a valuable technical tool for MG surveillance, MG eradication programs, and vaccine efficacy monitoring.Keywords: Mycoplasma gallisepticum (MG), Attenuated live vaccine, Duplex fluorescence quantitative PCR, DIVA Introduction Mycoplasma gallisepticum (MG) infection can cause chronic respiratory disease (CRD) in chickens and infectious sinusitis in turkeys (Chen, et al., 2026). Clinical signs of MG infection include respiratory rales, coughing, nasal discharge, and conjunctivitis, with turkeys frequently developing infraorbital sinusitis (Levisohn and Kleven, 2000). Infection with MG is considered to be for life (chronic), even with antibiotic treatment. Concurrent infections with other pathogens, including Mycoplasma synoviae (MS), Newcastle disease virus (NDV), infectious bronchitis virus (IBV), infectious laryngotracheitis virus (ILTV), and Escherichia coli, can lead to more severe airsacculitis and exacerbated respiratory symptoms (Bradbury, 1984; Kleven, et al., 1978). MG is one of the most impactful pathogens threatening the global poultry industry, and infection is reported worldwide. The World Organisation for Animal Health (WOAH) has included MG on its official notifiable animal disease list. MG can spread both vertically and horizontally within poultry flocks. In breeding flocks, MG infection increases flock culling rates, reduces egg production, lowers feed efficiency and hatchability, leading to substantial annual economic losses that also negatively impact international poultry trade. In many countries with well-established control and eradication programs, commercial breeding flocks are maintained free of MG infection, and broiler flocks, sourced from MG-free breeders, are likewise kept MG-negative. In addition, seroprevalence surveys have shown that a substantial proportion of commercial layer flocks are also MG-negative; for example, in the Netherlands, the seroprevalence of MG in commercial layers decreased from 6.3% to 1.9% over a 17-year period (ter Veen, et al., 2021). However, in countries or regions where MG remains endemic, and in flocks where MG-negative status is not maintained, live attenuated vaccination is one of the most effective means for controlling MG infection in poultry flocks. Currently, the three commercially licensed live attenuated MG vaccines most widely used globally are the F strain, the TS-11 strain, and the 6/85 strain. After immunization, the live vaccine strain adheres to and colonizes the poultry respiratory tract, where it primarily induces mucosal immunity. In addition to inducing mucosal and cell-mediated immunity, live attenuated MG vaccines can protect through competitive exclusion, whereby the vaccine strain colonizes the respiratory tract and outcompetes wild-type strains for adhesion receptors and nutrients, thereby preventing wild-type establishment (Levisohn and Kleven, 1981; Turner and Kleven, 1998). Sustained application of live attenuated vaccines in chicken farms can gradually replace circulating wild-type strains, ultimately achieving on-farm eradication of wild-type MG (Kleven, et al., 1990; Turner and Kleven, 1998). Despite the outstanding efficacy of live attenuated vaccines, they introduce a key challenge for MG monitoring: immunization with live attenuated vaccines alters host antibody levels, making it impossible to distinguish between vaccine strain and wild-type strain infections via conventional serological methods. To address this problem, molecular detection methods targeting genetic differences between wild-type and vaccine strains have been developed to achieve accurate differentiation (Hong, et al., 2005; Sulyok, et al., 2019; Xin, et al., 2026). To date, whole-genome sequences of multiple MG field isolates and all three commercial vaccine strains (F, TS-11, and 6/85) have been obtained, and several specific genetic differences between wild-type and vaccine strains have been identified as targets for differential detection. Traditional differentiation methods include random amplification of polymorphic DNA (RAPD), arbitrarily primed PCR (AP-PCR), and amplified fragment length polymorphism (AFLP). However, these methods generally require prior pathogen isolation, are time-consuming, and are not suitable for large-scale clinical detection. To overcome these limitations, more convenient and rapid molecular methods have been established, including high-resolution melting (HRM) analysis, mismatch amplification mutation assays (MAMAs), and real-time quantitative PCR (qPCR) (Callison, et al., 2006; Raviv and Kleven, 2009). This study developed a set of duplex fluorescent quantitative PCR (duplex qPCR) methods that can distinguish MG wild-type strains from vaccine strains, and achieve specific detection of each target strain. We analyzed the whole-genome sequences of MG wild-type strains and vaccine strains, and screened out strain-specific polymorphic sites, while integrating the differential loci reported in previous literature. Based on the identified specific sites, we designed multiple sets of specific primers and Minor Groove Binder (MGB) probes, and finally screened out four sets of optimal primer-probe combinations. Each set can specifically detect either the wild-type strain, or one of the three vaccine strains respectively. By pairing the wild-type-specific primer-probe set with each of the three vaccine strain-specific sets separately, we successfully established three duplex qPCR assays, all of which can achieve simultaneous detection of two targets. When the established assays were applied to clinical sample detection, they successfully distinguished wild-type field strains from vaccine strains according to the type of vaccine used on the farm. Materials and methods Mycoplasma gallisepticum strains The Rlow strain (Accession No. CVCC1651) was obtained from the China Veterinary Microbial Culture Collection and Management Center (CVCC). The live MG vaccine strains (F-36, TS-11, and 6/85) were obtained from commercial vaccine products kindly provided by cooperating poultry farms (manufacturers: F-36, Qingdao Yebio Biological Engineering Co., Ltd., HuYiJia; TS-11, Australian BioResources Pty Ltd, Vaxsafe® MG; 6/85, MSD Animal Health, MYCOVAC L®). Genomic sequences of all MG strains included in this study (with their accession numbers listed in Table 1) were retrieved from the NCBI GenBank database. Table 1MG isolates and vaccine strains in NCBI.Table 1 dummy alt textStrainsTypeAccession numberRlowWildAE015450F-36VaccineCP173072TS-11VaccineCP0442256/85VaccineCP044224S6WildCP006916RhighLaboratory strainCP001872NCTC10115WildLS991952mx-4WildCP044226NY01_2001.047-5-1PWildCP003509NC08_2008.031-4-3PWildCP003513CA06_2006.052-5-2PWildCP003512NC06_2006.080-5-2PWildCP003511WI01_2001.043-13-2PWildCP003510NC96_1596-4-2PWildCP003508NC95_13295-2-2PWildCP003507VA94_7994-1-7PWildCP003506Ap3ASWildCP044624f99Laboratory strainCP028146PG31WildCP143981G4WildCP1439922266WildCP158274KUVMG001WildCP0706222713WildCP158634G6WildCP143991 MG isolates and vaccine strains in NCBI. Primer and probe design Whole-genome alignment was performed using DNASTAR MegAlign software (DNASTAR, Inc., Madison, WI, USA) to identify polymorphic sites between the wild-type strain and all vaccine strains. Based on the identified strain-specific polymorphic sites, we designed specific primers and MGB probes for the wild-type strain and each vaccine strain, with their sequences provided in Table 2, Table 3. The specificity of all primers and probes was verified via BLAST alignment against the NCBI database. All oligonucleotides were synthesized by GenScript (Nanjing, China). Table 2Specific sites of MG wild-type and vaccine.Table 2 dummy alt textStrainsGeneTargets copiesSourceWildCrmAsingleThis studyFCrmAsingleThis studyTS-11CRISPRsingleKang, et al., 20236/85GapAsingleSulyok, et al., 2019 Specific sites of MG wild-type and vaccine. Table 3Primers and probes designed.Table 3 dummy alt textPrimer/ProbeSequences (5’→3’)MG-W-Uni-FCCTAAATCTGGTGCGCCTACAMG-W-Uni-RTATTCTTTGGGAGCGGTTGGTMG-W-Uni-PFAM-ACCAACTGCTCCTAAG-MGBMG-F36-FGATCACAAATTGGATTAGCTAGAACATCTMG-F36-RGTTCTAATATTCTTAATTGATGAGAACTGATCACMG-F36-PVIC-CAGTAACCCCTCGTGAT-MGBMG-TS11-FTAGTGTTTTGTGGTTTGTTAATMG-TS11-RAACTCTTTACGACATCAATAGCMG-TS11-PVIC-CTAAATATCAAACTCGAACAAG-MGBMG-6/85-FCAACGAAAGTGCATTAAGTATTGGTGMG-6/85-RGTTTTGGTGTTTCCTGGAGCTTCMG-6/85-PVVIC-CAGTTCCGTTTTCAAA-MGBMGB: Minor Groove Binder Primers and probes designed. MGB: Minor Groove Binder Specificity evaluation MG cultures (Rlow, F-36, TS-11, and 6/85 strains) were grown as described in Supplementary File 4. Five milliliters of each culture was centrifuged at 12,000 × g for 10 min. Genomic DNA was extracted from each culture using the Bacterial Genomic DNA Kit (CWBIO, Taizhou, China) following the manufacturer's instructions. The specificity of each primer-probe set was evaluated using DNA extracted from the Rlow strain and the three vaccine strains as templates. Each 20 μL reaction mixture was prepared as follows: 10 μL of 2 × qPCR probe premix (Vazyme, Nanjing, China), 400 nM each of forward and reverse primer, 200 nM probe, 2 μL of DNA template, and nuclease-free water to adjust the final volume to 20 μL. Amplification reactions were performed on a Bioer 9600 PLUS system (Bioer Technology, Hangzhou, China) with the following thermal cycling program: initial denaturation at 95°C for 5 min, followed by 40 cycles of denaturation at 95°C for 10 s and annealing/extension at 60°C for 30 s. Fluorescence signals were collected during the 60°C step of each cycle. Standard Curve Establishment, Repeatability, and Sensitivity Evaluation Primers listed in Table 3 were used to amplify DNA from the Rlow, F-36, TS-11, and 6/85 strains. The amplification products were gel-purified and ligated into the pEASY-T3 cloning vector (TransGen Biotech, Beijing, China), then transformed into TransI-T1 competent cells (TransGen Biotech, Beijing, China). The copy number of each recombinant plasmid was calculated based on the plasmid concentration, size, and Avogadro’s constant (see Supplementary File S5 for details). Each recombinant plasmid was prepared into ten-fold serial dilutions ranging from 1 × 101 to 1 × 108 copies/μL, which were used as templates for qPCR amplification following the reaction conditions described above. After amplification, the built-in software of the instrument automatically generated the standard curve and calculated core parameters including amplification efficiency, curve slope, and R2. To assess intra-assay and inter-assay reproducibility, we used plasmid dilutions at three concentrations of 1 × 105, 1 × 106, and 1 × 107 copies/μL. Each concentration was tested in triplicate in both intra-assay and inter-assay replicates. Finally, the coefficient of variation (CV) was calculated based on the Cq values obtained from all replicates. The CV(%)=(standarddeviationofCqvaluesmeanCqvalue)×100%. A Duplex Real-time PCR Assay for Differential Detection of Wild-type and Three Major Vaccine Strains of Mycoplasma gallisepticum In this assay, MG wild-type strain probes and vaccine strain probes were labeled with different fluorophores (Table 3). By combining the primers and probes targeting wild-type and vaccine MG strains, we established a duplex fluorescent quantitative PCR method that can simultaneously detect both wild-type MG and vaccine MG strains. After preliminary screening, the optimal reaction conditions for the established duplex qPCR were determined (Supplementary Material S1). The optimal 20 μL reaction system consisted of: 10 μL 2 × qPCR probe premix (Vazyme, Nanjing, China), 400 nM each of wild-type-specific forward/reverse primers and vaccine strain-specific forward/reverse primers, 200 nM each of wild-type-specific probe and vaccine strain-specific probe, 2 μL of serially diluted template (1 × 101 to 1 × 107 copies/μL, prepared as described above), and nuclease-free water added to adjust to the final volume. The thermal cycling procedure was consistent with the protocol described above. Fluorescence signals were collected in the FAM channel and VIC channel to realize duplex detection. After the reaction was completed, the instrument software automatically generated a standard curve and calculated relevant parameters including amplification efficiency, slope, and R2. Evaluation Using Clinical Samples A total of 660 choanal cleft swab samples were collected from layer and breeder chicken flocks across Shandong, Jiangsu, and Hebei provinces, and the Ningxia Hui Autonomous Region of China. Of these, 200 samples were obtained from flocks vaccinated with the F-36 strain, 180 from flocks vaccinated with the TS-11 strain, and 120 from flocks vaccinated with the 6/85 strain. In addition, 160 clinical samples were collected from unvaccinated chicken flocks as negative controls. Samples were collected either before vaccination or within 8 weeks post-vaccination (before the onset of lay) to evaluate pre-vaccination wild-type status and early vaccine strain colonization. Genomic DNA was extracted from the swab samples using a heat lysis method. Briefly, collected samples were centrifuged to pellet cellular debris, the supernatant was discarded, and the resulting pellet was resuspended in nuclease-free water. The suspension was boiled for 10 min, followed by a second centrifugation step, and the final supernatant (containing purified DNA) was harvested for subsequent qPCR analysis. The extracted DNA was used as the template for the duplex qPCR assay developed in this study, with amplification performed under the reaction conditions described in the preceding section. Results Primers and probes We first identified strain-specific polymorphic sites between the wild-type and vaccine strains of MG, and designed and optimized corresponding primers and MGB probes based on these sequences (Table 2, Table 3). After experimental verification, we confirmed that both the wild-type MG and the F-36 vaccine strain use the CrmA gene as the detection target, but target different strain-specific polymorphic sites within this gene. In addition, we identified CRISPR as the strain-specific marker for the TS-11 vaccine strain, and GapA as the strain-specific marker for the 6/85 vaccine strain (Fig. 1). BLAST analysis verified the specificity of the selected primers and probes, and confirmed that the screened target genes have MG species specificity. Sequence alignment of MG strains and design of strain-specific primers and probes. (A) Wild-type; (B) TS-11; (C) F-36; (D) 6/85. For each strain, the polymorphic site and the positions of the forward primer, reverse primer, and MGB probe are indicated. Specificity of the qPCR Both the wild-type-specific and vaccine strain-specific probes exhibited high specificity. All primer combinations only generated amplification curves when the DNA of the corresponding target strain was used as a template, and no amplification was detected when DNA of the non-target strain was used as template (Fig. 2). Furthermore, when DNA extracted from other common avian respiratory pathogens including MS, NDV, IBV and ILTV was used as the template, no specific amplification curve was observed in the assay. This result further confirmed the good specificity of the established detection method (Supplementary File S2). Specificity of the four single-plex qPCR assays for wild-type and vaccine strains. DNA from the Rlow (wild-type), F-36, TS-11, and 6/85 strains was used as template. Each assay produced amplification curves only with its target strain DNA. (A) Wild-type-specific assay; (B) F-36-specific assay; (C) TS-11-specific assay; (D) 6/85-specific assay. Standard curves, reproducibility, and sensitivity The detection limit of the established method was 10 copies/μL for both wild-type MG strains and the three vaccine strains. Standard curves for each strain were generated, with representative amplification curves provided in Supplementary Figure S1. The linear regression equations (Supplementary Figure S2), amplification efficiencies, and R² values are summarized in Table 4. Reproducibility assessment showed that in both intra-assay and inter-assay analyses, the coefficient of variation (CV) of Cq values across all plasmid concentration groups was below 0.3% (Table 5). Table 4Standard curve parameters for each strain (single-plex qPCR).Table 4 dummy alt textStrainEquationAmplification efficiencyR2Wild-typey = -3.27x + 39.28102.06%1.000F-36y = -3.32x + 39.6100.05%0.999TS-11y = -3.45x + 39.695.02%0.9996/85y = -3.21x + 38.18105.01%0.999 Standard curve parameters for each strain (single-plex qPCR). Table 5Reproducibility of MG wild strains and vaccine strains detection method.Table 5 dummy alt textTemplatesPlasmid concentration (copy/μL)Intra-assayInter-assayCq value (mean ± standard deviation)Coefficient of variation (%)Cq value (mean ± standard deviation)Coefficient of variation (%)wild strains106 copy/μL18.63 ± 0.060.3018.70 ± 0.020.082105 copy/μL22.35 ± 0.010.0522.34 ± 0.020.093104 copy/μL25.81 ± 0.030.1025.84 ± 0.010.039F strains106 copy/μL19.00 ± 0.030.1618.97 ± 0.030.16105 copy/μL22.51 ± 0.010.0322.52 ± 0.020.09104 copy/μL26.02 ± 0.040.1626.00 ± 0.020.07TS-11 strains106 copy/μL20.80 ± 0.050.2420.74 ± 0.020.07105 copy/μL24.75 ± 0.060.2524.88 ± 0.070.28104 copy/μL27.97 ± 0.070.2528.00 ± 0.030.016/85 strains106 copy/μL18.60 ± 0.0060.0318.60 ± 0.020.08105 copy/μL21.91 ± 0.040.1621.88 ± 0.030.12104 copy/μL25.23 ± 0.060.0725.20 ± 0.030.12 Reproducibility of MG wild strains and vaccine strains detection method. A duplex qPCR method for discriminating between wild-type and vaccine strains of mycoplasma gallisepticum The established duplex qPCR assays enabled simultaneous detection of wild-type and vaccine strains (Supplementary Figure S3). To evaluate the performance of the assays, standard curves were generated using serially diluted plasmids ranging from 10¹ to 10⁷ copies/μL. Standard curves were generated for each duplex qPCR assay. The detection limit for all assays was 10 copies/μL. All standard curves demonstrated excellent linearity (R² = 0.999) with amplification efficiencies ranging from 95.02% to 105.01%, well within the acceptable range of 90–110% (Table 6). Representative amplification curves are provided in Supplementary Figure S3. Table 6Standard curve parameters for each duplex qPCR assay (All R² values are 0.999).Table 6 dummy alt textDuplex assayTarget StrainEquationAmplification efficiencyF-36/WildWild-typey = -3.26x + 36.1998.29%F-36y = -3.51x + 37.7997.16%TS-11/WildWild-typey = -3.36x + 38.1498.29%TS-11y = -3.39x + 37.9497.16%6/85/WildWild-typey = -3.32x + 36.43100.07%6/85y = -3.26x + 36.07102.60% Standard curve parameters for each duplex qPCR assay (All R² values are 0.999). Clinical sample detection In total, we collected 660 choanal cleft swab samples from farms that used different live vaccines, as well as from non-vaccinated farms. Among all collected samples, 540 were obtained from flocks vaccinated with live attenuated vaccines (F-36, TS-11, and 6/85 strains), and the remaining 120 were collected from unvaccinated flocks. Detailed sample information is provided in Table 7. When we tested samples from flocks immunized with the F-36, TS-11, or 6/85 strain as templates, positive signals were detected by both the wild-type-specific assay and the corresponding vaccine strain-specific assay. In contrast, when testing samples from unvaccinated flocks, positive signals were only detected by the wild-type-specific assay (Fig. 3). Notably, no clinical samples were found to be positive for more than one vaccine strain, nor were any samples co-positive for both vaccine and wild-type strains. These results confirm that the developed duplex qPCR assay can achieve accurate, rapid, and specific detection of wild-type strains and vaccine strains in clinical samples. Table 7Sampleinformation and detection results.Table 7 dummy alt textImmunizationNumber of samplesWildF-36TS-116/85F-36 strain2002412600TS-11 strain1803006806/85 strain120160060Not vaccinated16025000 Sampleinformation and detection results. Amplification curves of the duplex qPCR assay for clinical samples. DNA extracted from choanal cleft swabs was used as template. (A) Representative curves from a TS-11-vaccinated flock. (B, C) Two representative curves from an F-36-vaccinated flock. (D, E) Two representative curves from a 6/85-vaccinated flock. (F) Representative curves from an unvaccinated flock. Positive signals were detected in all vaccinated flocks, while only the wild-type-specific assay produced signals in the unvaccinated flock. Discussion Mycoplasma gallisepticum (MG) remains a major challenge for the global poultry industry, owing to its high transmissibility, ability to establish persistent infections, and severe negative impact on poultry production performance. Currently, the key control measures for MG include Mycoplasma freedom, drug therapy, and vaccination. Long-term application of antibiotics for MG control has led to varying degrees of antimicrobial resistance in avian mycoplasma isolates. Although MG isolates from multiple countries have shown elevated MIC values against several commonly used antibiotics (Bottinelli, et al., 2022; Zhang, et al., 2022), strict biosecurity measures combined with live attenuated MG vaccination can effectively prevent the spread of the pathogen. In countries with established poultry improvement plans, effective epidemiological monitoring provides the data needed to guide the culling of infected flocks, verify the progress of eradication, and certify MG-free status. Through these actions, the gradual eradication of MG can be achieved(Feberwee, et al., 2022). However, the application of live attenuated MG vaccines complicates epidemiological surveillance: effective monitoring requires specific detection methods capable of distinguishing wild-type strains from vaccine strains. Currently available MG detection methods mainly include bacterial isolation and identification, serological testing, and molecular testing. Serological testing is relatively simple and suitable for large-scale screening; however, it cannot distinguish whether antibodies are induced by vaccine or wild-type strains. Bacterial isolation and identification is the gold standard for MG detection, but it takes a long time (4-30-day wait for growth) and is not sensitive. Often, field isolates grow very poorly on laboratory media, limiting its application in rapid large-scale detection(Khalifa, et al., 2013). Molecular detection methods, including conventional PCR and real-time PCR, enable rapid detection of MG DNA. On this basis, a variety of detection assays based on strain-specific molecular markers have been developed to distinguish between wild-type MG strains and vaccine strains (Xue, et al., 2024). Real-time quantitative PCR (qPCR) provides rapid and sensitive detection, making it ideal for large-scale clinical sample testing and epidemiological investigations. Among qPCR detection reagents, MGB probes are widely applied in nucleic acid detection and SNP genotyping. Compared with traditional TaqMan probes, MGB probes are more suitable for genotyping assays. Vaxsafe®MS (MS-H strain, Bioproperties Ltd., Ringwood, Victoria, Australia) is the only attenuated live MS vaccine approved for use in China. Based on the genetic differences between the MS-H vaccine strain and wild-type field isolates, researchers have developed an MGB probe method that can differentiate between wild-type MS strains and the MS-H vaccine strain (Chen, et al., 2025). This method can accurately distinguish wild-type strains from vaccine strains in clinical samples, which effectively supports the efficacy evaluation of MS-H vaccination and the monitoring of wild-type MS infections. Drawing on this established differential detection idea, our study focused on Mycoplasma gallisepticum (MG), which faces more complicated challenges in strain differentiation. Although MG and MS both use live attenuated vaccines that offer comparable protective effects, MG has a wider variety of commercially used vaccines, making the differentiation between wild-type strains and vaccine strains far more challenging. To address this gap, we established a duplex qPCR method that can distinguish wild-type MG strains from the three most widely used MG vaccine strains. In this method, MGB probes were designed targeting strain-specific mutation sites, and verification confirmed that the method has excellent specificity. Compared with existing MG detection methods, our method shows clear advantages. In contrast to the previously reported TS-11-specific assay, which detects only TS-11 and non-TS-11 strains (Xue, et al., 2024), our method covers the three currently predominant live MG vaccine strains on the market, offering broader applicability. In addition, the reported quadruplex qPCR method cannot specifically identify wild-type MG strains (Xin, et al., 2026), whereas our method realizes specific detection of wild-type strains. A limitation of our method is that it does not detect the Australian wild-type strain Ap3AS, which shares the TS-11 target sequence. Since this genotype has not been reported in China and our assay performed well on all Chinese clinical samples, we believe the method is suitable for its primary application. In regions where Ap3AS-related strains may occur (e.g., Australia), we recommend combining our assay with a universal MG qPCR (WOAH, 2024) to ensure comprehensive detection. Laboratory simulation confirmed that the method can detect co-infections of MG wild-type and vaccine strains; however, no such co-infected clinical samples were identified in the present study. It has been confirmed that F-36 and TS-11 vaccine strains can spread horizontally among flocks (Kleven, 1981; Ley, et al., 1997). Unvaccinated flocks may be infected via horizontal transmission from adjacent vaccinated flocks, e.g., through indirect transmission by personnel or equipment. It should be noted that a detection strategy targeting only the wild-type and one vaccine strain may overlook horizontally transmitted non-immunized strains. These are typically commercial vaccine strains that exhibit relatively low pathogenicity in chickens. Nevertheless, they can be identified using the appropriate vaccine-specific primer-probe set. Moreover, a key feature of our method is its ability to detect co-infections of wild-type and vaccine strains, which may be particularly valuable for farms where such complex situations potentially exist. The four primer-probe sets developed in this study target wild-type Mycoplasma gallisepticum strains and the three major vaccine strains (F-36, TS-11, and 6/85). In principle, by optimizing fluorescent labels, a multiplex qPCR assay can be established to simultaneously detect wild-type strains and all three vaccine strains in a single reaction. Considering the practical application of attenuated live vaccines in production settings, a single farm typically does not use more than two MG attenuated live vaccines simultaneously. Therefore, these farms generally only need to employ the corresponding vaccine/wild-type duplex qPCR assay to evaluate vaccine strain colonization and monitor wild-type strain infections. The objective of this study was to develop an accurate, rapid, and sensitive discriminatory detection method suitable for long-term clinical sample testing. While meeting the basic requirements of discriminatory detection, the method must also balance detection cost and detection efficiency. Including more oligonucleotide components may reduce detection performance and increase testing costs. Therefore, after comprehensive evaluation, we selected the duplex qPCR format for method development. This selection is based on the practical application characteristics of MG attenuated live vaccines in production: a single farm usually does not use more than two types of MG attenuated live vaccines at the same time. From a cost-benefit perspective, these farms only need to use the corresponding vaccine/wild-type duplex qPCR assay to achieve vaccine strain colonization evaluation and wild-type infection monitoring. For special scenarios, corresponding expansion schemes are also available. For farms that use multiple attenuated live vaccines or have replaced vaccine strains, the replaced vaccine strain may still persist and spread in the breeding area (Khalifa, et al., 2014; Ley, et al., 1993). For such cases, detection can be performed using a single-plex method specific to the corresponding vaccine strain, or a triplex qPCR assay targeting wild-type and two vaccine strains can be constructed by replacing the corresponding fluorescent dyes. For countries or regions that use other attenuated vaccine strains such as K5054 strain (Ferguson-Noel and Williams, 2015; Ferguson, et al., 2004), by analyzing the whole genome of these vaccine strains to identify specific targets, new specific primers and probes can be designed and combined with the wild-type specific primers and probes developed in this study to achieve discriminatory detection. This method enables both qualitative detection and quantitative analysis of wild-type and vaccine strains. All standard curves of the method exhibit excellent linear relationships, with slopes of regression equations ranging from -2.9 to -3.8 and amplification efficiencies falling between 90% and 110%, both of which meet the standard requirements for qPCR methods (de Gonzalo-Calvo, et al., 2022). In terms of sensitivity, our method is at least 100-fold higher than conventional PCR (Kang, et al., 2023), and its performance approaches or even surpasses that of existing real-time qPCR assays. Compared with conventional PCR, this method eliminates the need for downstream gel electrophoresis, which is more convenient to operate and particularly suitable for high-throughput clinical sample testing. In terms of detection specificity and application performance, there is no cross-signal interference between the fluorescence signals of different probes. In addition to accurately detecting pure cultured DNA in laboratory environments, this method can also achieve accurate detection of actual clinical samples. Clinical sample testing results show that wild-type strain infections exist in multiple geographic regions. To verify the compatibility of the method with different instruments, we tested its effectiveness on multiple mainstream real-time quantitative PCR instruments, including the ABI 7500 Real-Time PCR System (Thermo Fisher, China) and the Real-Time Quantitative Thermal Cycler FMR3 (Vazyme, China). All test results confirmed that the method can successfully distinguish between wild-type and vaccine strains on different platforms. Most of the clinical samples tested in this study were collected from commercial laying hens in large-scale farms, with very few samples derived from breeding chickens or broilers. In terms of sample types, the specimens included in this study are also relatively limited: the majority were choanal cleft swabs, and there was a lack of tissue samples from organs such as fallopian tubes and brain, which are common sites of systemic infection caused by Mycoplasma gallisepticum (MG). In addition to choanal cleft swabs, a limited number of cloacal swabs and tracheal tissue samples were also tested, all of which were negative for MG; these were not included in the primary analysis. Existing studies have confirmed that after MG infects the host respiratory tract, it can spread to organs such as fallopian tubes and brain through the bloodstream to cause systemic infection, reduces host production performance (Nunoya, et al., 1997), and triggers neurological symptoms (Wyrzykowski, et al., 2013). For future research, we propose the following suggestions: First, the sample collection scope should be expanded in terms of geography and host range, including more diverse poultry species (e.g., turkeys, ducks) as well as chickens of different ages and breeds, to fully verify the general applicability of the detection method established in this study. Second, the detection performance of this assay for samples co-infected with wild-type MG strains and vaccine strains still needs further evaluation, which will help comprehensively assess the stability and reliability of this method in practical application scenarios. CRediT authorship contribution statement Pengcheng Fan: Writing – review & editing, Writing – original draft, Visualization, Validation, Software, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. Ziqing Liu: Software, Resources, Methodology. Yi Xu: Validation, Formal analysis, Data curation. Mengjiao Guo: Writing – review & editing, Supervision. Chengcheng Zhang: Writing – review & editing, Software. Zongyi Bo: Writing – review & editing, Visualization, Methodology. Yantao Wu: Writing – review & editing, Project administration, Funding acquisition. Xiaorong Zhang: Writing – review & editing, Supervision, Project administration, Funding acquisition. Disclosures The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Acknowledgments This research was supported by China Agriculture Research System of MOF and MARA (CARS-40); National Key R&D Program of China (2023YFD1800201); a Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD). Footnotes Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.psj.2026.107094. Fig. S1. Representative amplification curves of the single-plex qPCR assays for wild-type and vaccine strains. Ten-fold serial dilutions of plasmid standards (ranging from 10¹ to 10⁸ copies/μL) were used as templates. (A) Wild-type-specific assay; (B) F-36-specific assay; (C) TS-11-specific assay; (D) 6/85-specific assay. Fig. S2. Standard curves for the wild-type and vaccine strain-specific qPCR assays. Ten-fold serial dilutions of plasmid standards (10¹–10⁸ copies/μL) were used as templates. Each panel shows the linear regression of log copy number against Cq value, with the coefficient of determination (R²) and amplification efficiency indicated. (A) Wild-type-specific assay; (B) F-36-specific assay; (C) TS-11-specific assay; (D) 6/85-specific assay. Fig. S3. Amplification and standard curves of the three duplex qPCR assays. Using ten-fold serial dilutions of plasmid standards (10¹–10⁸ copies/μL). Upper panels (A–C): amplification curves; lower panels (D–F): corresponding standard curves (slope and efficiency indicated). (A, D) Wild-type/F-36; (B, E) Wild-type/TS-11; (C, F) Wild-type/6/85. Supplementary materials Fig. S1. Representative amplification curves of the single-plex qPCR assays for wild-type and vaccine strains. Ten-fold serial dilutions of plasmid standards (ranging from 10¹ to 10⁸ copies/μL) were used as templates. (A) Wild-type-specific assay; (B) F-36-specific assay; (C) TS-11-specific assay; (D) 6/85-specific assay. Fig. S2. Standard curves for the wild-type and vaccine strain-specific qPCR assays. Ten-fold serial dilutions of plasmid standards (10¹–10⁸ copies/μL) were used as templates. Each panel shows the linear regression of log copy number against Cq value, with the coefficient of determination (R²) and amplification efficiency indicated. (A) Wild-type-specific assay; (B) F-36-specific assay; (C) TS-11-specific assay; (D) 6/85-specific assay. Fig. S3. Amplification and standard curves of the three duplex qPCR assays. Using ten-fold serial dilutions of plasmid standards (10¹–10⁸ copies/μL). Upper panels (A–C): amplification curves; lower panels (D–F): corresponding standard curves (slope and efficiency indicated). (A, D) Wild-type/F-36; (B, E) Wild-type/TS-11; (C, F) Wild-type/6/85. References Associated Data Supplementary Materials Fig. S1. Representative amplification curves of the single-plex qPCR assays for wild-type and vaccine strains. Ten-fold serial dilutions of plasmid standards (ranging from 10¹ to 10⁸ copies/μL) were used as templates. (A) Wild-type-specific assay; (B) F-36-specific assay; (C) TS-11-specific assay; (D) 6/85-specific assay. Fig. S2. Standard curves for the wild-type and vaccine strain-specific qPCR assays. Ten-fold serial dilutions of plasmid standards (10¹–10⁸ copies/μL) were used as templates. Each panel shows the linear regression of log copy number against Cq value, with the coefficient of determination (R²) and amplification efficiency indicated. (A) Wild-type-specific assay; (B) F-36-specific assay; (C) TS-11-specific assay; (D) 6/85-specific assay. Fig. S3. Amplification and standard curves of the three duplex qPCR assays. Using ten-fold serial dilutions of plasmid standards (10¹–10⁸ copies/μL). Upper panels (A–C): amplification curves; lower panels (D–F): corresponding standard curves (slope and efficiency indicated). (A, D) Wild-type/F-36; (B, E) Wild-type/TS-11; (C, F) Wild-type/6/85.